Anzeige
Mehr »
Dienstag, 15.09.2026 - Börsentäglich über 12.000 News
80,4 g/t Gold und 131 g/t Silber: Was, wenn die alten Minen erst der Anfang waren?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
BI

WKN: 1888 | ISIN: DEXXXXXXX122 | Ticker-Symbol: -
Branche
Pharma
Aktienmarkt
nicht börsennotiert
1-Jahres-Chart  (nicht börsennotiert)
BOEHRINGER INGELHEIM GMBH Chart 1 Jahr
ACCESS Newswire
1.389 Leser
Artikel bewerten:
(1)

Boehringer Ingelheim: Sugar Clinics: A One-Stop Shop for Improved Diabetes Care in Mexico

For millions of people, diabetes is not just a health condition-it is a daily reality that influences how they live, work, and plan their futures. In Mexico, the situation is particularly urgent: National data show that nearly one in five adults lives with diabetes, highlighting its high prevalence. Moreover, diabetes is one of the leading causes of death in the country, underscoring its significant public health impact.

NORTHAMPTON, MA / ACCESS Newswire / September 15, 2026 / For many, the journey to manage diabetes is as challenging as the diagnosis itself. Fragmented public healthcare pathways often force patients to spend months navigating care. They move from one facility to another before receiving the full treatment they need-if they can afford it at all. These systemic challenges result in long delays, rising personal costs, and growing treatment fatigue-turning accessing care and adherence to treatment into a constant balancing act with everyday life.

When systems struggle, innovation emerges

In such a fragmented landscape, continuity of care is far from guaranteed. Chronic diseases like diabetes bring not only physical complications such as chronic kidney disease and heart failure, but also financial strain, emotional burden, and persistent stigma. The impact reaches beyond the individual-placing pressure on their families, communities, and in the end the healthcare system as a whole.

Traditional healthcare structures, while essential, often struggle to address the full spectrum of patient needs-particularly in underserved communities. This gap has created an opportunity for alternative, high-quality clinical care delivered by multidisciplinary teams, improving accessibility, affordability, and continuity.

Partnership as a catalyst for systemic change

Enter Clínicas del Azúcar (Sugar Clinics): an innovative social enterprise, established in 2010, providing affordable diabetes care to underserved communities across Mexico. Their business model addresses these challenges head-on: they offer integrated care-including diagnostics, consultations, nutrition and psychological support-all under one umbrella as a "one-stop shop" solution.

Combined with operational excellence, this streamlined model significantly enhances the patient experience: while fragmented public care pathways can take months, Clínicas del Azúcar consolidates diagnostics, consultation, and support into a single visit.

At costs well below comparable private specialist care, they make high-quality diabetes care accessible, and support sustained disease management, helping to reduce the risk of complications, including those affecting cardiovascular, renal, and metabolic health.

Over the past decade, this integrated model has successfully evolved into a growing network of clinics across Mexico and has now crossed the border into the United States, signaling its relevance beyond a single national context.

Specialized care: Access

Established in 2010, the chain now operates a network of over 50 specialized diabetes clinics across communities in Mexico.

Treatment options: Value

Guided by cost benchmarks, Clínicas developed a membership model designed to make diabetes care more affordable.

Therapy adherence: Care

Addressing fragmented care, which often leads diabetes patients in Mexico to interrupt or stop treatment due to access barriers.

Looking ahead: Health systems built for tomorrow

In a country like Mexico, where diabetes, cardiovascular disease, and kidney conditions represent critical public health challenges, innovative models of care are increasingly significant. Partnerships that combine scientific expertise, operational innovation, and social entrepreneurship offer new pathways to address complex realities. The evolving collaboration between Boehringer Ingelheim Mexico and Clínicas del Azúcar illustrates how cross-sector approaches can help shape more accessible, coordinated, and resilient healthcare systems.

As chronic diseases continue to rise globally, such initiatives highlight the importance of rethinking how healthcare is delivered-not only to treat illness, but also to support sustained diabetes management in communities with historically limited access to integrated care.

Our collaboration

The collaboration between Boehringer Ingelheim Mexico and Clínicas del Azúcar began in 2010 with early-stage support that helped establish the first clinic in Mexico City. Since then, the partnership has developed into a long-term initiative focused on expanding access to early diagnosis, treatment, and sustained disease management.

A milestone includes a membership-based program launched by two Boehringer employees that allows local colleagues to access Clínicas del Azúcar's services at no cost. The program was designed as a model to encourage other companies to provide employees with access to specialized, comprehensive care to prevent or manage diabetes. To date, it is part of the benefits offered by more than 40 companies.

Through recent investments, such as through Boehringer's Social Engagement Fund, new clinics are being established to serve additional communities. This partnership reflects a shared belief that healthcare innovation often emerges at the intersection of entrepreneurial thinking, scientific rigor, and local understanding.

Read more on Imagine - Boehringer Ingelheim's sustainability story hub.

Find more stories and multimedia from Boehringer Ingelheim at 3blmedia.com.

Contact Info:
Spokesperson: Boehringer Ingelheim
Website: https://www.3blmedia.com/profiles/boehringer-ingelheim
Email: info@3blmedia.com

SOURCE: Boehringer Ingelheim



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sugar-clinics-a-one-stop-shop-for-improved-diabetes-care-in-mexico-1221166

© 2026 ACCESS Newswire
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.